<DOC>
	<DOCNO>NCT01178086</DOCNO>
	<brief_summary>This observational study assess therapeutic efficiency , treatment schedule handle procedure , safety profile MabThera/Rituxan ( rituximab ) routine care patient chronic lymphocytic leukemia . Data patient collect total 24 month .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic lymphocytic leukemia require treatment Patients receive chemotherapy combination MabThera/Rituxan ( decision take doctor prior independent inclusion noninterventional study ) Comorbidities accord CIRS score &gt; 6 and/or creatinine clearance &lt; 70 ml/min Unable unwilling give inform consent Contraindication MabThera/Rituxan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>